2 assets in Sweat Gland Carcinoma

Therapeutic assets addressing Sweat Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Sweat Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Sweat Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)